Histological changes of the rat liver after administration of imatinib mesylate: an experimental study

Luma Ibrahim Khalil Al-Allaf, Hafidh Al-Ashoo
Department of Anatomy, College of Medicine, University of Mosul, Mosul, Iraq.
Correspondence: Lumaalalf1971@yahoo.com

ABSTRACT

Objectives: This study aims to determine the histological changes of the liver of rats after administration of a low dose or a clinically relevant high dose of Imatinib mesylate for one month in comparison to control ones.

Study setting and design: This experimental study was performed over a period of four months starting from the 10th March 2013 to the 10th July 2013 and was conducted on male Albino rats purchased from Animal Houses of both Mosul Medical College, and Veterinary College, University of Mosul, Mosul, Northern Iraq.

Methods: The first experiment includes 40-45 days aged rats who administered orally daily dose of 75mg/Kg of imatinib mesylate (Glivec®; Novartis) purchased from IBN-SENA Teaching Hospital, Mosul and bought from some private pharmacies for 30 days with age matched control who administered distilled water. The second experiment includes 40-45 days aged rats who administered daily dose of 200mg/Kg orally with age matched control who administered distilled water. Liver of rats from each experimental group were obtained. The tissues were embedded in paraffin and stained with hematoxylin-eosin and periodic acid schiff stain.

Results: The histological examination of the liver tissues of groups receiving imatinib at doses of 75 mg/kg or 200mg/kg on daily for 30 days duration showed different degrees of various histological changes of damage when compared with the control group. Male rats administered with 75 mg/kg of imatinib resulted moderate degree of several histological changes. The most striking feature is disruption in radial arrangement around central vein, sinusoidal dilatation, and hepatocytes with eosinophilic cytoplasm. Perivenular inflammatory cells, accumulation of inflammatory cells. Loss of cellular outline, and loss of euchroma in of the hepatocytes. Light microscopic examination of sections obtained from liver tissues of groups receiving imatinib at dose of 200mg/kg revealed similar changes, however, these changes were more pronounced in comparison to those in low dose group.

Conclusion: Imatinib causes hepatotoxicity even in low dose group (75mg/kg, however, it has a dose dependent effect but to some extent. Appropriate protective measures must be applied with anticancer treatment for improving liver function.

Keywords: Imatinib mesylate, chronic myelogenous leukemia, hepatotoxicity.
The long-term treatment of CML patients with imatinib is associated with a decreased risk of secondary neoplasms, mainly myeloid/lymphoid neoplasms with eosinophilia and abnormalities of chromosome 17 (MENA).

The treatment of CML with imatinib has provided great benefits for patients, and it has been shown to improve survival and reduce progression to blast crisis. However, long-term treatment with imatinib has been associated with several side effects, including hematologic abnormalities, gastrointestinal disorders, and cardiovascular events. Therefore, it is important to monitor patients closely and adjust treatment regimens as necessary. It is also important to research new treatment options for CML, such as novel tyrosine kinase inhibitors and targeted therapies.
around 5% is excreted unchanged in urine\textsuperscript{15,16}. The main adverse effects include severe neutropenia and thrombocytopenia, oedema, fluid retention, nausea, mild diarrhoea, skin rashes, arthralgia, myalgia, bone pain, acute renal failure and hepatotoxicity\textsuperscript{17,18}. 

Hepatotoxicity has been observed in 5% of CML patients which show cytolytic hepatitis (including spotty and piecemeal necrosis), hepatic necrosis, and acute hepatitis. In spite of the fact that hepatotoxicity resolved after imatinib discontinuation and steroids administration, in some patients, the hepatic condition further deteriorated leading to fatal liver failure\textsuperscript{19}. Histopathological findings revealed severe necrosis, cellular canalicular cholestasis, submassive acute hepatic necrosis and multiacinar hepatocellular necrosis\textsuperscript{20,21}. The majority of TKIs approved to date are reported to induce hepatic injury. Several studies reporting imatinib-induced hepatic lesions describe various types of changes in hepatocyte morphology. However, It is apparent that many important issues regarding the potential adverse effects of Imatinib on the liver need further clarification. This study aims to evaluate the histopathological changes that occur in liver of rats administered different regimens of imatinib mesylate (either low dose or high dose imatinib mesylate for one month duration) in comparison to the control ones.

Materials and Methods
This experimental study was performed over a period of four months starting from the 10th march 2013 to the 10th July 2013 and was conducted on male Albino rats purchased from Animal Houses of both Mosul Medical College, and Veterinary College, university of Mosul, Mosul, Northern Iraq.

Throughout the investigations the rats were housed under controlled normal environmental laboratory conditions and animal facility and were kept in an air-conditioned room with 12-hours light and dark cycles, where the temperature ($22 \pm 2$°C) and relative humidity(65–70%) were kept constant. They were local breaded and put individually in Animal House plastic cages\textsuperscript{22}. Animals were let to acclimatize for a week before any experiment was performed\textsuperscript{23}, and provided with free access of water ad libitum and pelleted standardized food\textsuperscript{24}. The experiments were performed during the light portion\textsuperscript{25}.

Experimental design and procedures
Mean bodyweight of all rats was 70-110 gm. The first experiment includes 40-45 days aged rats who administered daily dose of 75mg/Kg of imatinib mesylate (Glivec® Novartis) purchased from IBN-SENA Teaching Hospital or bought from some private pharmacies and were dissolved in distilled water and administered orally by gavage with 24 gage needle for 30 days (n=8) with age matched control who administered distilled water following the same protocol applied to imatinib group (n=4).

The second experiment includes 40-45 days aged rats who administered daily dose of 200mg/Kg orally by gavage with 24 gage needle for 30 days (n=8)with age matched control who administered distilled water following the same protocol applied to imatinib group (n=4).

Imatinib doses selected were intended to be in the range of those used in clinical treatment regimens\textsuperscript{26} (400-800 mg/d or 340-590 mg/m\textsuperscript{2} based on a weight of 70 kg) dose surface area adjusted to body-weight, \( f \times \text{mg/kg} = \text{mg/m}^2 \), where \( f \) is a constant equal to 6.0 in rats\textsuperscript{27}. Each animal was observed for overt signs of toxicity. The animals were firmly
restrained (the animal was grasped by the loose skin of the neck and back) to immobilize the head and maintained in an upright (vertical) position. The gavage needle was passed through the side of the mouth, followed the roof of the mouth, and advanced into the esophagus toward the stomach. After the needle was passed to the correct length, imatinib was injected.

**Study termination procedures**

Animals in each experiment were euthanized with ether 22, 29, 24 h after the final dose was given at laboratory of postgraduate studies of Department of Anatomy, Mosul College of Medicine, University of Mosul.

**Tissue and organs collection:** Liver portions of rats from each experimental group were obtained using longitudinal thoracoabdominal incision and they were immersed in NaCl solution 0.9% for few seconds in order to get rid of superficial blood. The liver was excised and examined macroscopically.

**Preparation of histological sections**

Liver were fixed in 10% Neutral buffered formalin, the tissues were embedded in paraffin (Merck, Germany) and stained with Harris hematoxylin-eosin (Scarla, Spain) and periodic acid schiff stain (PAS). The evaluation was blinded to treatment and any data. The tissue of hepatic samples were grossed and transferred into cassettes and processed as follows: (1) Two consecutive changes of solution of 10% Neutral buffered formalin 1 h and 1.5 h; (2) 85% Ethyl alcohol (Thomas baker, chemicals), limited, UK– 1.5 h; (3) 95% alcohol – 1.5 h; (4) 100% Alcohol – three consecutive changes of 1.5 h each; (5) xylene (Thomas baker, chemicals), limited, UK– three consecutive changes of 1.5 h each; and (6) paraffin bath at 55°C – two changes of 1.5 h each. Upon completion, the tissues were placed in 1.5x2cm moulds lined with molten paraffin wax at 65°C. The mould was transferred to a cold plate at -5°C, the tissue adjusted to the desired orientation and the cassette base placed on top of the mould, filled with molten wax and let to solidify for 1h, removed and then stored at -20°C until sectioning. The frozen embedded wax blocks were sectioned at 3-5 micron thickness using Reichert-Jung microtrom (Austria), placed on frosted glass slides and dried overnight at 37°C. Prior to modified Harris Haematoxylin and Eosin staining and periodic acid schiff stain (PAS) for general liver structure and periodic acid schiff (PAS) to demonstrate the glycogen deposition in hepatocytes respectively, the samples were washed in xylene twice (3 min each), hydrated in five sequential changes of alcohol 100%, 100%, 95%, 80% and 70% for 3 min each, rinsed with water for 3 min and stained. Finally, the stained slides were dehydrated in three sequential 1-min changes of alcohol 70%, 80%, and 95% and two changes of alcohol 100% for three minutes each. The sections were then dried and mounted onto the clean glass slides and labeled.

**Histopathological analysis**

Histopathology changes were observed for changes in toxicokinetic assessment including sinusoidal congestion, loss of cellular outline and lobular architecture, nuclear changes, and fatty changes. On the other hand, disruption in radial arrangement around central vein, sinusoidal dilatation, hepatocytes with eosinophilic cytoplasm, hydropic degeneration (cytoplasmic vacuolization and swelling of hepatocyte), and loss of the glycogen deposition in hepatocytes. These changes were grouped based on two main criteria: vascular changes including vessel congestion, sinusoidal dilatation, extravasation of red blood cells and hematoma formation; and...
necrotic changes including necrosis, fibrosis, nuclear changes, abscesses and cell regeneration.

The morphological changes were assessed semi-quantitatively to assess the extent of the histopathological changes, blind by an independent assessor and graded as follows: No change - 0 (no distinguishable change, 0%); mild change - 1 (initiation of changes, up to 30%); moderate change - 2 (patent changes, 31-60%); severe change - 3 (wide spread changes, 61-100%) for each criterion. Maximum score is noted as 9.

Photography
All sections were visualized in Bright field Olympus microscope (Japan). Photomicrographs of representative changes were taken using digital camera (Optika, Italy, HD 1080, resolution 8.0 Mega pixels) attached using planapochromatic objectives. The magnifications of photomicrograph will be indicated with the legends for the photograph.

Results
The histopathology assessment in liver was performed blindly for all groups. At necropsy, no obvious tissue abnormalities were noted in the liver of any animal. This study revealed that the light microscopic examination of the liver sections obtained from of the control group showed a normal appearance of the liver cells which appeared as normal large polygonal cells with prominent round nuclei and eosinophilic cytoplasm, and few spaced hepatic sinusoids arranged in-between the hepatic cords with fine arrangement of Kupffer cells (Figure 1,2).

The histological examination of the liver tissues of groups receiving imatinib at doses of 75 or 200mg/kg daily for 30 days showed different degrees of various histological changes of damage when compared with the baseline-control group. Male rats administered with 75 mg/kg of imatinib resulted moderate degree of several histological changes (Table 1). The most striking feature is disruption in radial arrangement around central vein, sinusoidal dilatation, and hepatocytes with eosinophilic cytoplasm (Figure 3). Perivenular inflammatory cells, accumulation of inflammatory cells were shown in Figures 4,5,6.

Loss of cellular outline, and loss of euchromatin of the hepatocytes were noticed in sections obtained from the liver tissues of group receiving imatinib at doses of 75 mg/kg (Figures 5,6,7).

Light microscopic examination of sections obtained from liver tissues of groups receiving imatinib at dose of 200mg/kg revealed similar changes; however, these changes were more pronounced in comparison to those in low dose group (Figures 8,9,10,11,12,13).

Moreover, high dose group showed various features of nuclear alterations of hepatocytes including anisocytosis (Figure 9), presence of dense apoptotic nuclei (Figure 12). In addition, swelling of hepatocytes were also noticed (Figure 9,13).

Feathery degeneration was shown obviously especially in sections obtained from liver tissues of groups receiving imatinib at dose of 200mg/kg (Figure 11).

Microscopic damage score for each group was determined and results were given in Table 1.

Figures 14,15 shows the decreased amount of glycogen in the sections obtained from the liver tissues of groups receiving imatinib at doses of 75 or 200mg/kg respectively.
Table 1. Comparison of the effect of imatinib on microscopic structure in liver in all groups

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control Group</th>
<th>Low dose Group</th>
<th>High dose Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microscopic damage</td>
<td>0.6</td>
<td>4.9</td>
<td>5.1</td>
</tr>
</tbody>
</table>

Figure 1. A photomicrograph of a section obtained from the liver of rat of control group with normal histological appearance (H&E ×400).

Figure 2. A photomicrograph of section obtained from the liver of rat of control group showed the PAS-positive reaction shows a magenta staining where glycogen is present within hepatocytes (PAS ×250).

Figure 3. A photomicrograph of section obtained from the liver of rat treated with low dose of imatinib showed disruption of radial arrangement of hepatic cords, dilation of sinusoid, presence of esinophilic stained hepatocytes (H&E ×250).

Figure 4. A photomicrograph of section obtained from the liver of rat treated with low dose of imatinib showed disruption of radial arrangement of hepatic cords, presence of few perivenular inflammatory cells (H&E ×250).

Figure 5. A photomicrograph of section obtained from the liver of rat treated with low dose of imatinib showed disruption of radial arrangement of hepatic cords, dilated sinusoids, accumulation of inflammatory cells and esinophilic hepatocytes with loss of euchromatin and cellular outline (H&E ×400).

Figure 6. A photomicrograph of section obtained from the liver of rat treated with low dose of imatinib showed disruption of radial arrangement of hepatic cords, dilated sinusoids, accumulation of inflammatory cells in perivenular area and esinophilic hepatocytes with loss of euchromatin (H&E ×250).
Figure 7. A photomicrograph of section obtained from the liver of rat treated with low dose of imatinib showed disruption of radial arrangement of hepatic cords, obliterated sinusoids, and eosinophilic hepatocytes with loss of cellular outline (H&E ×400).

Figure 8. A photomicrograph of section obtained from the liver of rat treated with high dose of imatinib showed congested portal vein and sinusoids, presence of accumulated inflammatory cells with eosinophilic stained hepatocytes (H&E ×400).

Figure 9. A photomicrograph of section obtained from the liver of rat treated with high dose of imatinib showed swelling of hepatocytes with degeneration and loss of euchromatin, area of dissolution of hepatic cords was noticed (H&E ×600).

Figure 10. A photomicrograph of section obtained from the liver of rat treated with high dose of imatinib showed congested portal vein, dilation of sinusoid, presence of eosinophilic stained hepatocytes (H&E ×250).

Figure 11. A photomicrograph of section obtained from the liver of rat treated with high dose of imatinib showed disruption of radial arrangement of hepatic cords, eosinophilic hepatocytes with loss of euchromatin and cellular outline, and feathery degeneration (H&E ×250).

Figure 12. A photomicrograph of section obtained from the liver of rat treated with high dose of imatinib showed eosinophilic hepatocytes with loss of euchromatin and cellular outline, hepatocytes with apoptotic nuclei are also seen (H&E ×400).

Figure 13. A photomicrograph of section obtained from the liver of rat treated with high dose of imatinib showed eosinophilic hepatocytes with loss of euchromatin and cellular outline, swelling of hepatocytes with anisocytosis are also noticed (H&E ×400).
Discussion
Drugs targeting tumor-specific pathways are believed to be more effective than conventional chemotherapeutic drugs, which tend to affect rapidly dividing cells in both normal and cancerous tissues. Targeted small molecule drugs have revolutionized treatment of CML over the last decade. The introduction of small-molecule TKIs in clinical oncology has transformed the treatment of certain forms of cancers. However, their use has been found to be associated with serious toxic effects on a number of vital organs including the liver. This study revealed many histopathological abnormalities in the liver. These findings are in accordance with that of Cohen et al, who reported presence of hepatotoxicity after 2 weeks of imatinib administration in dogs. The histological assessment revealed mild focal hepatocellular necrosis, single cell bile duct necrosis and bile duct hyperplasia (associated with peribiliary fibrosis). However, Seggara et al revealed the histological findings in mice with lesser degree of toxicity which may be anticipated since they used a single oral dose of imatinib (100 mg/kg); while the greater toxicity observed in the reported cases may be contributed by imatinib accumulation due to the multiple dosage administration. On the other hand, in humans, signs of liver dysfunction were found in CML patients with grade 3. In addition, fatal liver failure occurred in several cases. The pathogenic mechanisms of imatinib-induced hepatotoxicity are unknown. Research on the pathogenic mechanisms of imatinib-induced hepatotoxicity suggests that toxicity may be related to the P450 mediated metabolic pathway or idiosyncratic reactions in susceptible individuals. A study which was done by Sherif et al showed comparable results were obtained with the rat’s liver following treatment with imatinib, he suggested that the histopathological investigation showed hydropic changes and attributed that to the increase in NO production (reflected in the total NOx content level). Augmentation of cardiotoxicity following treatment with imatinib with arsenic might be attributed to imatinib-induced PDGF receptor and c-Ab1 blockade.

On the other hand, chemotherapeutic agents such as cisplatin, doxorubicin, and 5-FU cause direct hepatic toxicity including inflammatory cells forming...
granulomatous lesions and periportal fibrosis and apoptosis. It has been suggested that Doxorubicin has been shown to induce accumulation of inflammatory cells, associated with increased activities of tissue aminotransferases, lactate dehydrogenase and alkaline phosphatase, indicating hepatic damage via induction of apoptosis and generation of reactive oxygen radicals.

A recent article suggested that activation of endoplasmic reticulum stress after imatinib is a cause of imatinib-induced cardiomyopathy. Any pathological state that leads to increased production and/or ineffective scavenging of reactive oxygen species may play a crucial role in determining tissue injury. The administration of cyclophosphamide damages the liver. Tissue damage due to cyclophosphamide might be alleviated due to the antioxidant property and membrane stabilizing property of melatonin. It is known that eosinophilic-stained cells show the starting irreversible damage in the tissue. On the other hand, there were degenerative changes as swelling of hepatocytes (reversible damage) in the rat treated with methotruxate, and that is attributed to oxidative stress. This study showed many histopathological abnormalities in the liver including inflammatory infiltration, hyperplasia, periportal fibrosis, marked disruption of hepatic cords and dilated blood sinusoids. Many hepatocytes showed karyomegaly and pyknotic nuclei indicating apoptosis. Cell death can result from naturally occurring apoptosis (physiological apoptosis) or from irreparable cell injury (pathological apoptosis) as described by Farber in 1994. Apoptosis is a common feature of hepatotoxicity induced by many chemicals; it may precede necrosis, as in the hepatotoxicity induced by thioacetamide, or it may occur concurrently with necrosis as in hepatotoxicity associated with acetaminophen. This study showed that the hepatotoxic effect of imatinib was more pronounced in high dose group in comparison with that in low dose, these finding is in accordance with that of Kerkela et al in 2006 and Sook Han et al in 2009 who reported that the response to imatinib may be dose and tissue dependent.

In conclusion Appropriate protective measures must be applied with anticancer treatment for improving liver function. This study provide an in-vivo evidence, at light microscopic, of direct chemotherapeutic hepatotoxicity caused by imatinib. Furthermore, this study identified pathological features at structural level, which could be used as the basis for determining the appropriate dose of these drugs to reduce their hepatotoxic effects. Post-marketing experience with drugs such as imatinib, lapatinib and sorafenib suggests that the hepatotoxic safety of all the TKIs requires diligent surveillance.

References
29. Saad SY, Alkhafy KH, Arafah MM. Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats. JPP 2006,58:1–7